A Rollover Study of CC-122
← catalyst calendarNCT05688475 · readout in 73 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
12estimated
Sites
7
Countries
France, Japan, Netherlands +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-11 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Hodgkin Lymphoma
Interventions
- Drug: CC-122 — also filed as Avadomide, BMS-986381
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122
measured Up to approximately 3 years
Number of deaths for participants who received at least 1 dose of CC-122
measured Up to approximately 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed